WhiteOak Capital Pharma and Heathcare Fund Direct Plan Growth
WhiteOak Capital Asset Management Limited · Direct Plan · Growth
Fund overview
NIL
Returns & rankings
| Period | Fund Returns | Category Avg. | Rank | VS Category |
|---|---|---|---|---|
| … | ||||
Green = fund outperformed the category average for that period; red = underperformed. Periods under 1 year always show absolute (non-annualised) returns. Past performance does not guarantee future returns.
Return calculator
One-time investment
₹1,000
| Over the past | Total investment | Would've become | Returns |
|---|---|---|---|
| 1 Year | ₹1,000 | ₹1,199 | +199 |
| 3 Years | ₹1,000 | ₹1,724 | +724 |
| 5 Years | ₹1,000 | ₹2,478 | +1,478 |
Calculated using the fund's annualised return since inception (19.9% p.a.) as period-wise historical returns aren't available in the current feed. Actual returns fluctuate and are not guaranteed. Mutual fund investments are subject to market risks.
Holdings
59 securitiesTop 10 holdings make up 44.8% of the portfolio.
| Security | Sector | Market Cap | Weight |
|---|---|---|---|
| Divi'S Laboratories Ltd | Pharmaceuticals & Biotechnology | Large Cap | 8.36% |
| Sun Pharmaceutical Industries Ltd | Pharmaceuticals & Biotechnology | Large Cap | 7.11% |
| Torrent Pharmaceuticals Ltd | Pharmaceuticals & Biotechnology | Large Cap | 6.26% |
| Clearing Corporation of India Ltd | Cash/Deposits/Margins/Treps/Repo/Swaps | — | 5.55% |
| Laurus Labs Ltd | Pharmaceuticals & Biotechnology | Mid Cap | 3.91% |
| Apollo Hospitals Enterprises Ltd | Healthcare Services | Large Cap | 3.75% |
| Cipla Ltd | Pharmaceuticals & Biotechnology | Large Cap | 3.68% |
| SAI Life Sciences Ltd | Pharmaceuticals & Biotechnology | Small Cap | 3.28% |
| Ipca Laboratories Ltd | Pharmaceuticals & Biotechnology | Mid Cap | 2.88% |
| Zydus Lifesciences Ltd | Pharmaceuticals & Biotechnology | Mid Cap | 2.81% |
Portfolio Allocation
Equity / Debt / Cash
Total Value
₹927 Cr
Market Cap Split
Total Value
100%
Equity sector allocation
Total Value
₹841 Cr
Debt sector allocation
Total Value
₹29 Cr
Allocation By Credit Quality (Debt)
Exit load, stamp duty & tax
06-Feb-24
NIL
0.005% (from July 1st, 2020)
Taxation depends on the fund category and holding period. Consult the scheme document or a tax advisor for details.
Risk & Performance Ratios (1Y)
| Standard Deviation | -- |
| Beta | -- |
| Sharpe Ratio | -- |
| Sortino Ratio | -- |
| Treynor Ratio | -- |
| Jensen's Alpha | -- |
| Information Ratio | -- |
| R-Squared | -- |
| Max Drawdown | -- |
| Upside Capture | -- |
| Downside Capture | -- |
Fund management
Scheme Details
Investment objective
The Primary Objective Of The Scheme Is To Provide Long-Term Capital Appreciation By Investing Predominantly In Equity And Equity Related Instruments Of Pharma And Healthcare Companies.
Fund house
WhiteOak Capital Asset Management Limited
Frequently asked questions
What is the NAV of WhiteOak Capital Pharma and Heathcare Fund Direct Plan Growth?
The NAV of WhiteOak Capital Pharma and Heathcare Fund Direct Plan Growth is ₹16.35 as of 21 Oct 2026. NAV is updated at the end of every trading day.
How much expense ratio is charged by WhiteOak Capital Pharma and Heathcare Fund Direct Plan Growth?
The expense ratio charged by WhiteOak Capital Pharma and Heathcare Fund Direct Plan Growth is 1.09%.
What is the Min. SIP of WhiteOak Capital Pharma and Heathcare Fund Direct Plan Growth?
The minimum SIP investment in WhiteOak Capital Pharma and Heathcare Fund Direct Plan Growth is ₹100 per month.
What is the Min. Lumpsum of WhiteOak Capital Pharma and Heathcare Fund Direct Plan Growth?
The minimum lumpsum investment in WhiteOak Capital Pharma and Heathcare Fund Direct Plan Growth is ₹500.
What is the Exit Load of WhiteOak Capital Pharma and Heathcare Fund Direct Plan Growth?
The exit load for WhiteOak Capital Pharma and Heathcare Fund Direct Plan Growth is: NIL
.svg){kind=small}